瑞舒伐他汀和阿托伐他汀对早发急性心肌梗死血清心肌损伤标志物水平的影响分析

Effects of Rosuvastatin and Atorvastatin on Serum Myocardial Injury Markers Levels in Patients with Early-onset Acute Myocardial Infarction

目的分析比较瑞舒伐他汀和阿托伐他汀对早发急性心肌梗死(AMI)血清心肌损伤标志物水平的影响。方法选取我院104例早发AMI患者为研究对象,采用随机数字表法分为瑞舒伐他汀组(观察组,n=52)和阿托伐他汀组(对照组,n=52)。比较两组治疗前及治疗6个月后血脂水平[低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]、炎症反应[超敏C-反应蛋白(hs-CRP)、乳脂肪球表皮生长因子8(MFG-E8)]、心肌损伤标志物水平[肌酸激酶同工酶(CK-MB)、超敏肌钙蛋白T(hs-TnT)]差异。结果治疗6个月后,两组血清LDL-C、hs-CRP及血浆CK-MB、hs-TnT水平均较治疗前降低(P<0.05),血清HDL-C、MFG-E8水平则较治疗前升高(P<0.05),且观察组变化幅度均大于对照组(P<0.05)。结论瑞舒伐他汀及阿托伐他汀用于治疗早发AMI效果均较好,但瑞舒伐他汀对患者血脂调节、炎症抑制、心肌损伤改善等作用优于阿托伐他汀,于患者病情转归更有利。

Objective To compare the effects of rosuvastatin and atorvastatin on serum myocardial injury markers levels in earlyonset acute myocardial infarction(AMI).Methods A total of 104 patients with early-onset AMI in our hospital were selected for the study and were divided into rosuvastatin group(observation group,n=52)and atorvastatin group(control group,n=52)according to the random number table method.The blood lipids levels[low-density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C)],inflammatory response[hypersensitive C-reactive protein(hs-CRP),milk fat globule epidermal growth factor 8(MFG-E8)]and myocardial injury markers levels[creatine kinase isoenzyme(CK-MB),hypersensitive troponin T(hs-TnT)]were compared between the two groups before treatment and after 6 months of treatment.Results After 6 months of treatment,levels of serum LDL-C,hs-CRP,and plasma CK-MB and hs-TnT in the two groups were decreased compared with those before treatment(P<0.05)while levels of serum HDL-C and MFG-E8 were increased compared with those before treatment(P<0.05),and the changes in observation group were greater than those in control group(P<0.05).Conclusion Rosuvastatin and atorvastatin both have good effects in the treatment of early-onset AMI,but rosuvastatin is superior to atorvastatin in improving blood lipids regulation,inflammation inhibition and myocardial injury,and it is more favorable for disease outcomes.